- Home
- LSTA vs RLMD Comparison
LSTA vs RLMD Comparison
Compare LSTA & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSTA
- RLMD
- Stock Information
- Founded
- LSTA 1980
- RLMD 2004
- Country
- LSTA United States
- RLMD United States
- Employees
- LSTA N/A
- RLMD N/A
- Industry
- LSTA Misc Health and Biotechnology Services
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- LSTA Health Care
- RLMD Health Care
- Exchange
- LSTA Nasdaq
- RLMD Nasdaq
- Market Cap
- LSTA 20.9M
- RLMD 22.0M
- IPO Year
- LSTA N/A
- RLMD N/A
- Fundamental
- Price
- LSTA $2.94
- RLMD $0.67
- Analyst Decision
- LSTA Strong Buy
- RLMD Buy
- Analyst Count
- LSTA 1
- RLMD 3
- Target Price
- LSTA $15.00
- RLMD $5.00
- AVG Volume (30 Days)
- LSTA 9.3K
- RLMD 478.7K
- Earning Date
- LSTA 08-11-2025
- RLMD 08-06-2025
- Dividend Yield
- LSTA N/A
- RLMD N/A
- EPS Growth
- LSTA N/A
- RLMD N/A
- EPS
- LSTA N/A
- RLMD N/A
- Revenue
- LSTA $1,000,000.00
- RLMD N/A
- Revenue This Year
- LSTA N/A
- RLMD N/A
- Revenue Next Year
- LSTA N/A
- RLMD N/A
- P/E Ratio
- LSTA N/A
- RLMD N/A
- Revenue Growth
- LSTA N/A
- RLMD N/A
- 52 Week Low
- LSTA $1.87
- RLMD $0.24
- 52 Week High
- LSTA $4.20
- RLMD $4.47
- Technical
- Relative Strength Index (RSI)
- LSTA 66.20
- RLMD 52.84
- Support Level
- LSTA $2.36
- RLMD $0.67
- Resistance Level
- LSTA $2.69
- RLMD $0.72
- Average True Range (ATR)
- LSTA 0.20
- RLMD 0.08
- MACD
- LSTA 0.01
- RLMD -0.03
- Stochastic Oscillator
- LSTA 90.77
- RLMD 40.29
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.